Polio - Pipeline Review, Q1 2011

Document Sample
Polio - Pipeline Review, Q1 2011 Powered By Docstoc
					Polio – Pipeline Review, Q1 2011




                                  Polio - Pipeline Review, Q1 2011
                                                                                     Reference Code: GMDHC196IDB

                                                                                     Publication Date: March 2011




Polio – Pipeline Review, Q1 2011                                                                               GMDHC196IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                    Page(1)
Polio – Pipeline Review, Q1 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                2
List of Tables                                                                                                   3
List of Figures                                                                                                  3
Introduction                                                                                                     4
    Global Markets Direct Report Coverage                                                                        4
Polio Overview                                                                                                   5
Therapeutics Development                                                                                         6
    An Overview of Pipeline Products for Polio                                                                   6
Polio Therapeutics under Development by Companies                                                                8
Polio Therapeutics under Investigation by Universities/Institutes                                               10
Polio Therapeutics - Products under Development by Companies                                                    11
Polio Therapeutics - Products under Investigation by Universities/Institutes                                    13
Companies Involved in Polio Therapeutics Development                                                            14
    Sanofi-Aventis                                                                                              14
    GlaxoSmithKline plc                                                                                         14
Polio - Therapeutics Assessment                                                                                 16
    Assessment by Monotherapy Products                                                                          16
    Assessment by Combination Products                                                                          17
    Assessment by Route of Administration                                                                       18
    Assessment by Molecule Type                                                                                 20
Late Stage Drug Profiles – Companies                                                                            22
    Xepol - Drug Profile                                                                                        22
         Product Description                                                                                    22
         Mechanism of Action                                                                                    22
         R&D Progress                                                                                           22
    DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile                                                                  23
         Product Description                                                                                    23
         Mechanism of Action                                                                                    23
         R&D Progress                                                                                           23
    CombAct-HIB - Drug Profile                                                                                  24
         Product Description                                                                                    24
         Mechanism of Action                                                                                    24
         R&D Progress                                                                                           24
    CombAct-HIB + OPV - Drug Profile                                                                            26
         Product Description                                                                                    26
         Mechanism of Action                                                                                    26
         R&D Progress                                                                                           26
    Infanrix-IPV/Hib + Engerix-B - Drug Profile                                                                 28
         Product Description                                                                                    28
         Mechanism of Action                                                                                    28
         R&D Progress                                                                                           28
    ProQuad + Infanrix Hexa - Drug Profile                                                                      29
         Product Description                                                                                    29
         Mechanism of Action                                                                                    29
         R&D Progress                                                                                           29
    Hexaxim - Drug Profile                                                                                      30
         Product Description                                                                                    30


Polio – Pipeline Review, Q1 2011                                                          GMDHC196IDB / Pub March 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(2)
Polio – Pipeline Review, Q1 2011


          Mechanism of Action                                                                                                                                                                      30
          R&D Progress                                                                                                                                                                             30
    Quadracel - Drug Profile                                                                                                                                                                       31
          Product Description                                                                                                                                                                      31
          Mechanism of Action                                                                                                                                          
				
DOCUMENT INFO
Description: Polio - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Polio - Pipeline Review, Q1 2011', provides an overview of the Polio therapeutic pipeline. This report provides information on the therapeutic development for Polio, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio. 'Polio - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Polio. - A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Polio pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Polio. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries